tobramycin

Summary

Summary: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.

Top Publications

  1. pmc Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin
    Marshall C Walters
    Center for Biofilm Engineering, Department of Chemical Engineering, Montana State University Bozeman, Bozeman, Montana 59717 3980, USA
    Antimicrob Agents Chemother 47:317-23. 2003
  2. doi Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
    Michael W Konstan
    Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    J Cyst Fibros 10:54-61. 2011
  3. ncbi Aminoglycoside antibiotics induce bacterial biofilm formation
    Lucas R Hoffman
    Department of Pediatrics, University of Washington, Seattle, Washington 98195, USA
    Nature 436:1171-5. 2005
  4. ncbi Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent
    Thomas Bjarnsholt
    Centre for Biomedical Microbiology, BioCentrum, Technical University of Denmark, DK 2800 Lyngby, Denmark
    Microbiology 151:373-83. 2005
  5. pmc Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells
    Sophie Moreau-Marquis
    Department of Physiology, Dartmouth Medical School, Hanover, NH 03755, USA
    Am J Respir Cell Mol Biol 41:305-13. 2009
  6. doi Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model
    Louise D Christensen
    Department of International Health, Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen, DK 2200 Copenhagen, Denmark
    J Antimicrob Chemother 67:1198-206. 2012
  7. pmc Tobramycin at subinhibitory concentration inhibits the RhlI/R quorum sensing system in a Pseudomonas aeruginosa environmental isolate
    Fedora Babic
    Department of Biochemistry and Molecular Biology, University of Zagreb, Croatia
    BMC Infect Dis 10:148. 2010
  8. doi Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa
    Gloria Herrmann
    Institute of Medical Microbiology and Hygiene, Universitatsklinikum, University of Tubingen, Tubingen, Germany
    J Infect Dis 202:1585-92. 2010
  9. doi Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers
    Edward J Holland
    Cincinnati Eye Institute and University of Cincinnati, Cincinnati, OH, USA
    Cornea 27:50-5. 2008
  10. pmc Involvement of a novel efflux system in biofilm-specific resistance to antibiotics
    Li Zhang
    Department of Biochemistry, Microbiology and Immunology, 451 Smyth Road, University of Ottawa, Ottawa, ON, Canada K1N 8J2
    J Bacteriol 190:4447-52. 2008

Research Grants

Detail Information

Publications258 found, 100 shown here

  1. pmc Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin
    Marshall C Walters
    Center for Biofilm Engineering, Department of Chemical Engineering, Montana State University Bozeman, Bozeman, Montana 59717 3980, USA
    Antimicrob Agents Chemother 47:317-23. 2003
    ..b>Tobramycin and ciprofloxacin penetrated biofilms but failed to effectively kill the bacteria...
  2. doi Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
    Michael W Konstan
    Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    J Cyst Fibros 10:54-61. 2011
    A light-porous-particle, dry-powder formulation of tobramycin was developed, using PulmoSphere® technology, to improve airway delivery efficiency, substantially reduce delivery time, and improve patient convenience and satisfaction...
  3. ncbi Aminoglycoside antibiotics induce bacterial biofilm formation
    Lucas R Hoffman
    Department of Pediatrics, University of Washington, Seattle, Washington 98195, USA
    Nature 436:1171-5. 2005
    ..cells with a mutation changing a predicted catalytic residue of Arr were defective in their biofilm response to tobramycin. Furthermore, tobramycin-inducible biofilm formation was inhibited by exogenous GTP, which is known to inhibit c-..
  4. ncbi Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent
    Thomas Bjarnsholt
    Centre for Biomedical Microbiology, BioCentrum, Technical University of Denmark, DK 2800 Lyngby, Denmark
    Microbiology 151:373-83. 2005
    ..QS is blocked either by mutation or by administration of QS inhibitory drugs are sensitive to treatment with tobramycin and H2O2, and are readily phagocytosed by PMNs, in contrast to bacteria with functional QS systems...
  5. pmc Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells
    Sophie Moreau-Marquis
    Department of Physiology, Dartmouth Medical School, Hanover, NH 03755, USA
    Am J Respir Cell Mol Biol 41:305-13. 2009
    ..investigated whether the FDA-approved iron chelators deferoxamine and deferasirox would enhance the ability of tobramycin, the primary antibiotic used to treat CF lung infections, to eliminate P. aeruginosa biofilms...
  6. doi Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model
    Louise D Christensen
    Department of International Health, Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen, DK 2200 Copenhagen, Denmark
    J Antimicrob Chemother 67:1198-206. 2012
    Quorum sensing (QS)-deficient Pseudomonas aeruginosa biofilms formed in vitro are more susceptible to tobramycin than QS-proficient P...
  7. pmc Tobramycin at subinhibitory concentration inhibits the RhlI/R quorum sensing system in a Pseudomonas aeruginosa environmental isolate
    Fedora Babic
    Department of Biochemistry and Molecular Biology, University of Zagreb, Croatia
    BMC Infect Dis 10:148. 2010
    ..A few studies have demonstrated the effect of tobramycin as a signal molecule on gene expression at the transcriptional level and its effect on bacterial physiology and ..
  8. doi Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa
    Gloria Herrmann
    Institute of Medical Microbiology and Hygiene, Universitatsklinikum, University of Tubingen, Tubingen, Germany
    J Infect Dis 202:1585-92. 2010
    ..We tested the ability of colistin sulphate-tobramycin combinations and single antibiotics to kill P. aeruginosa biofilms.
  9. doi Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers
    Edward J Holland
    Cincinnati Eye Institute and University of Cincinnati, Cincinnati, OH, USA
    Cornea 27:50-5. 2008
    To compare the steroid-induced intraocular pressure (IOP) and other ocular adverse effects of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension with those of dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension.
  10. pmc Involvement of a novel efflux system in biofilm-specific resistance to antibiotics
    Li Zhang
    Department of Biochemistry, Microbiology and Immunology, 451 Smyth Road, University of Ottawa, Ottawa, ON, Canada K1N 8J2
    J Bacteriol 190:4447-52. 2008
    ..aeruginosa PA14 background results in an increase in sensitivity to tobramycin, gentamicin, and ciprofloxacin, specifically when this mutant strain is growing in a biofilm...
  11. pmc 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children
    Isabelle Cochereau
    Service d Ophtalmologie, CHU d Angers, 4, rue Larrey, 49033 Angers, France
    Br J Ophthalmol 91:465-9. 2007
    To compare the efficacy and safety of Azyter, azithromycin 1.5% eye drops, for 3 days with tobramycin 0.3% for 7 days to treat purulent bacterial conjunctivitis.
  12. doi Cationic amphiphiles increase activity of aminoglycoside antibiotic tobramycin in the presence of airway polyelectrolytes
    Kirstin R Purdy Drew
    Departments of Materials Science and Engineering, University of Illinois at Urbana Champaign, Urbana, Illinois 61801, USA
    J Am Chem Soc 131:486-93. 2009
    ..In this work, we use synchrotron small-angle X-ray scattering to investigate the interaction between tobramycin, an aminoglycoside antibiotic commonly administered to CF patients via inhalation, with DNA, which is found in ..
  13. ncbi Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro
    R Anderson
    Medical Research Council MRC Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria, and Tshwane Academic Division of the National Health Laboratory Service, South Africa
    J Antimicrob Chemother 60:1155-8. 2007
    ..azithromycin, clarithromycin, erythromycin, telithromycin, clindamycin, ciprofloxacin, moxifloxacin, tobramycin and doxycycline on pneumolysin production by a macrolide-susceptible strain and two macrolide-resistant strains [..
  14. ncbi Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system
    Juliane Hombach
    Institute of Pharmacy, Leopold Franzens University Innsbruck, Innrain 52, Josef Moller Haus, 6020 Innsbruck, Austria
    Eur J Pharm Sci 33:1-8. 2008
    The aim of the present study was to develop and evaluate an oral delivery system for tobramycin sulphate intended to improve the oral bioavailability...
  15. pmc Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function
    M Hentzer
    Department of Microbiology, Technical University of Denmark, 2800 Lyngby, Denmark
    J Bacteriol 183:5395-401. 2001
    ..strain exhibit a highly structured architecture and are significantly more resistant to the antibiotic tobramycin than a biofilm formed by an isogenic nonmucoid strain...
  16. doi Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery
    Gabrielle Pilcer
    Laboratory of Pharmaceutics and Biopharmaceutics, Universite Libre de Bruxelles, Belgium
    Int J Pharm 365:162-9. 2009
    ..Spray-drying was applied in order to retrieve nanoparticles in dried-powder state from tobramycin nanosuspensions...
  17. pmc Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model
    Marie Tre-Hardy
    Laboratoire de Chimie Biologique et Médicale et de Microbiologie Pharmaceutique, Institut de Pharmacie, Universite Libre de Bruxelles, CP 205 02, Bd du Triomphe, 1050 Brussels, Belgium
    Antimicrob Agents Chemother 54:4409-15. 2010
    ..The aim of this study was to compare the antimicrobial effects in vitro of the combinations tobramycin-clarithromycin and tobramycin-azithromycin against five P...
  18. doi Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
    Gregory S Sawicki
    Division of Respiratory Diseases, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA
    Pediatr Pulmonol 47:44-52. 2012
    Though tobramycin inhalation solution has been used for over a decade to improve lung function and reduce exacerbations in patients with cystic fibrosis (CF), its effects on mortality have not been well-described...
  19. pmc Involvement of an ATP-dependent protease, PA0779/AsrA, in inducing heat shock in response to tobramycin in Pseudomonas aeruginosa
    Kristen N Kindrachuk
    Centre for Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British Columbia, No 232, 2259 Lower Mall, Lower Mall Research Station, Vancouver, British Columbia V6T 1Z4, Canada
    Antimicrob Agents Chemother 55:1874-82. 2011
    ..aeruginosa to lethal, inhibitory, and subinhibitory concentrations of tobramycin under aerobic and anaerobic conditions...
  20. doi Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada ca
    Expert Rev Anti Infect Ther 10:459-73. 2012
    ....
  21. pmc Class 1 integron-associated tobramycin-gentamicin resistance in Campylobacter jejuni isolated from the broiler chicken house environment
    Margie D Lee
    Department of Medical Microbiology and Parasitology Athens Diagnostic Laboratory Department of Environmental Health Sciences, The University of Georgia, Athens, Georgia 30602, USA
    Antimicrob Agents Chemother 46:3660-4. 2002
    ..DNA sequencing demonstrated that all five isolates possessed the aminoglycoside resistance gene, aacA4...
  22. ncbi A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis
    Paul Scheinberg
    Atlanta Pulmonary Group, 5667 Peachtree Dunwoody Rd, Suite 350, Atlanta, GA 30350, USA
    Chest 127:1420-6. 2005
    To evaluate the efficacy and safety of tobramycin solution for inhalation (TSI) in patients with severe bronchiectasis.
  23. ncbi Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis
    Eric M White
    Complete Family Vision Care, San Diego, CA, USA
    Curr Med Res Opin 24:287-96. 2008
    This study compared the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T; Zylet) with dexamethasone 0.1%/tobramycin 0...
  24. doi Local delivery of tobramycin from injectable biodegradable polyurethane scaffolds
    Andrea E Hafeman
    Department of Chemical Engineering, 2301 Vanderbilt Place, VU Station B 351604, Vanderbilt University, Nashville, TN 37235, USA
    J Biomater Sci Polym Ed 21:95-112. 2010
    ..In this study, injectable PUR scaffolds incorporating tobramycin were prepared by reactive liquid molding...
  25. doi Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis
    Dominique Hubert
    CRCM adultes, Hopital Cochin, Assistance Publique des Hopitaux de Paris, France
    J Cyst Fibros 8:332-7. 2009
    Nebulization times have been identified as an issue in patient compliance with tobramycin solution for inhalation (TSI) therapy in cystic fibrosis (CF).
  26. doi NMR resonance assignments of an engineered neomycin-sensing riboswitch RNA bound to ribostamycin and tobramycin
    Sina R Schmidtke
    Institut für Molekulare Biowissenschaften, Johann Wolfgang Goethe Universität Frankfurt M, Max von Laue Str 9, 60438 Frankfurt, Germany
    Biomol NMR Assign 4:115-8. 2010
    ..the (1)H, (15)N, (13)C and partial (31)P chemical shift assignments for the minimal functional 27nt neomycin sensing riboswitch RNA in complex with the 4,5-linked neomycin analog ribostamycin and the 4,6-linked aminoglycoside tobramycin.
  27. doi Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis
    E L Guy
    Leeds Regional Paediatric Cystic Fibrosis Centre, St James s University Hospital, Leeds, LS9 7TF, United Kingdom
    J Cyst Fibros 9:292-5. 2010
    Safety and toxicity data for nebulised tobramycin are mainly derived from use of the Pari LC Plus nebuliser, yet many centres are now using advanced nebulisers, such as the eFlow.
  28. ncbi Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis
    David E Geller
    Nemours Children s Clinic, Division of Pulmonology, Orlando, FL 32806, USA
    Chest 122:219-26. 2002
    To describe the pharmacokinetics and bioavailability of inhaled tobramycin (TOBI; Chiron Corporation; Seattle, WA), 300-mg dose, delivered by a nebulizer (PARI LC Plus; Pari Respiratory; Richmond, VA) and a compressor (Pulmo-Aide, model ..
  29. pmc Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms
    Giorgia Borriello
    Center for Biofilm Engineering and Department of Clinical Engineering, Montana State University Bozeman, 409 Cobleigh Hall, Bozeman, Montana 59717 3980, USA
    Antimicrob Agents Chemother 50:382-4. 2006
    Arginine enhanced the killing of Pseudomonas aeruginosa by ciprofloxacin and tobramycin under anaerobic, but not aerobic, growth conditions...
  30. pmc Targeting a bacterial stress response to enhance antibiotic action
    Samuel Lee
    Departments of Genome Sciences and Medicine and Microbiology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 106:14570-5. 2009
    ..in a screen of a comprehensive, defined transposon mutant library for functions whose inactivation increased tobramycin sensitivity...
  31. pmc In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells
    Gregory G Anderson
    Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
    Infect Immun 76:1423-33. 2008
    ..Treatment of P. aeruginosa biofilms with tobramycin reduced the virulence of the biofilms both by reducing bacterial numbers and by altering virulence gene ..
  32. ncbi Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
    Richard B Moss
    Department of Pediatrics, Stanford University Medical Center, Palo Alto, CA 94304 5786, USA
    Chest 121:55-63. 2002
    ..To determine the effect of long-term suppression of Pseudomonas aeruginosa on lung function and other clinical end points in adolescent patients with cystic fibrosis (CF)...
  33. pmc Enhancement of antimicrobial activity against pseudomonas aeruginosa by coadministration of G10KHc and tobramycin
    Randal Eckert
    UCLA School of Dentistry, 10833 Le Conte Avenue, Los Angeles, CA 90095 1668, USA
    Antimicrob Agents Chemother 50:3833-8. 2006
    ..aeruginosa. G10KHc was found to be highly active (as active as tobramycin) against P. aeruginosa clinical isolates...
  34. pmc Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis
    David L MacLeod
    Gilead Sciences, Inc, Seattle, WA 98121, USA
    J Antimicrob Chemother 64:829-36. 2009
    To compare the in vitro and in vivo activities of a 4:1 (w/w) fosfomycin/tobramycin combination (FTI) with those of fosfomycin and tobramycin alone against cystic fibrosis (CF) and non-CF bronchiectasis pathogens.
  35. ncbi Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment
    D L MacLeod
    Department of Research Biology, PathoGenesis Corp, Seattle, WA 98119, USA
    J Infect Dis 181:1180-4. 2000
    ..in Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients during a recent clinical trial of inhaled tobramycin. Impermeability, in which bacteria have reduced susceptibility to all aminoglycosides, was the predominant mode ..
  36. doi Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis
    Gail L Torkildsen
    Andover Eye Associates, Andover, MA 01810, USA
    Curr Med Res Opin 27:171-8. 2011
    To evaluate the clinical efficacy and safety of tobramycin/dexamethasone (TobraDex ST ; 'ST') ophthalmic suspension 0.3%/0...
  37. ncbi Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis
    Christian A Merlo
    The Johns Hopkins University School of Medicine, 1830 E Monument St Fifth Floor, Baltimore, MD 21205, USA
    Chest 132:562-8. 2007
    ..The main objective of the study was to estimate the incidence and identify risk factors for the acquisition of MARPA among individuals with CF...
  38. pmc Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips
    María I Morosini
    Servicio de Microbiologia, Hospital Universitario Ramon y Cajal, Madrid, Spain
    J Clin Microbiol 43:4480-5. 2005
    Inhaled administration of tobramycin assures high concentrations in cystic fibrotic lungs, improving the therapeutic ratio over that of parenteral tobramycin levels, particularly against Pseudomonas aeruginosa...
  39. ncbi Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients
    Gabrielle Pilcer
    Laboratory of Pharmaceutics and Biopharmaceutics, Universite Libre de Bruxelles, Brussels, Belgium
    Eur J Pharm Biopharm 68:413-21. 2008
    b>Tobramycin dry powder formulations were evaluated by gamma scintigraphy and pharmacokinetic methods...
  40. ncbi Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin
    Jesus Hermida
    Laboratorio Central, Hospital Clinico Universitario, 15706 Santiago de Compostela, Spain
    Ther Drug Monit 28:326-31. 2006
    ..In 130 hospitalized patients who were administered amikacin, gentamicin, tobramycin, and vancomycin by intermittent intravenous infusion, we compared the predicted GFR values from the serum ..
  41. ncbi Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis
    David Adeboyeku
    Department of Cystic Fibrosis, Royal Brompton Hospital, Sydney Street, London, UK
    J Cyst Fibros 5:261-3. 2006
    A previous study of tobramycin nebuliser solution (TNS) compared with colistin [C] in cystic fibrosis (CF) patients, chronically infected with pseudomonas, showed benefit for the TNS treated patients over one treatment cycle only...
  42. pmc Electrolytic generation of oxygen partially explains electrical enhancement of tobramycin efficacy against Pseudomonas aeruginosa biofilm
    P S Stewart
    Center for Biofilm Engineering, Montana State University Bozeman 59717 3980, USA
    Antimicrob Agents Chemother 43:292-6. 1999
    ..oxygen, hydrogen, and heat, in mediating electrical enhancement of killing of Pseudomonas aeruginosa biofilms by tobramycin (the bioelectric effect) was investigated...
  43. doi Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial
    Irini P Chatziralli
    Department of Ophthalmology, Veroia General Hospital, 28 Papanastasiou Street, Veroia, Greece
    Ophthalmologica 225:89-94. 2011
    ....
  44. doi Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment
    Giuseppe Valenza
    Institute of Hygiene and Microbiology, University of Wurzburg, Wurzburg, Germany
    Scand J Infect Dis 42:885-9. 2010
    b>Tobramycin and colistin represent 2 standard antimicrobial agents in the treatment of cystic fibrosis (CF) patients who are chronically colonized with Pseudomonas aeruginosa...
  45. pmc In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli
    R J Fass
    Department of Internal Medicine, Ohio State University College of Medicine, Columbus 43210, USA
    Antimicrob Agents Chemother 40:1412-8. 1996
    ..ampicillin-sulbactam, piperacillin, piperacillin-tazobactam, ceftazidime, cefoperazone, ceftriaxone, imipenem, tobramycin, and trimethoprim-sulfamethoxazole (TMP-SMZ) were determined for 308 isolates, representing 13 species, by a ..
  46. doi Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms
    Carole Nagant
    Laboratoire de Chimie Biologique et Médicale et de Microbiologie Pharmaceutique, Institut de Pharmacie, Universite Libre de Bruxelles, Brussels, Belgium
    Appl Microbiol Biotechnol 88:251-63. 2010
    ..eight strains of Pseudomonas aeruginosa (both reference and clinical strains) and compared with the response to tobramycin. In planktonic cultures, the minimal inhibitory and minimal bactericidal concentrations of CSA-13 and tobramycin ..
  47. doi Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes
    Misagh Alipour
    The Novel Drug and Vaccine Delivery Systems Facility, Department of Chemistry and Biochemistry, Laurentian University, Sudbury, Ontario, P3E 2C6, Canada
    J Antimicrob Chemother 65:684-93. 2010
    This study examined the activities of tobramycin and bismuth against quorum sensing, virulence factors and biofilms of Pseudomonas aeruginosa by co-encapsulating the agents in liposomes in order to achieve greater delivery of the agents.
  48. doi Optimization of capillary electrophoresis method with contactless conductivity detection for the analysis of tobramycin and its related substances
    Mohamed Nouri El-Attug
    Laboratory for Pharmaceutical Analysis, Faculteit Farmaceutische Wetenschappen, Katholieke Universiteit Leuven, O and N 2, PB 923, Herestraat 49, B 3000 Leuven, Belgium
    J Pharm Biomed Anal 58:49-57. 2012
    A method was validated and optimized to determine tobramycin (TOB) and its related substances. TOB is an aminoglycoside antibiotic which lacks a strong UV absorbing chromophore or fluorophore...
  49. doi Prophylaxis of catheter-related bacteremia using tissue plasminogen activator-tobramycin locks
    Ali Mirza Onder
    West Virginia University, WVU HSC, Morgantown, 26506 9214, USA
    Pediatr Nephrol 24:2233-43. 2009
    This retrospective study was designed to investigate the effectiveness of tissue plasminogen activator-tobramycin antibiotic lock solutions (TPA/tobra ABLs) for prophylaxis of catheter-related bacteremia (CRB) in high-risk children on ..
  50. pmc Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections
    Ronald Gounden
    Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa
    BMC Infect Dis 9:26. 2009
    ..Nosocomial infections due to multi-drug resistant Acinetobacter baumannii are often treated with colistin, but there are few data comparing its safety and efficacy with other antimicrobials...
  51. pmc Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection
    Moayad Alhariri
    Novel Drug and Vaccine Delivery Systems Facility, Department of Chemistry and Biochemistry, Laurentian University, Sudbury, ON, Canada
    Antimicrob Agents Chemother 57:569-78. 2013
    ..as well as the in vivo antimicrobial activity of bismuth-ethanedithiol incorporated into a liposome-loaded tobramycin formulation (LipoBiEDT-TOB) administered to rats chronically infected with P. aeruginosa...
  52. pmc Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa
    G L Drusano
    Ordway Research Institute, Albany, New York, USA
    Antimicrob Agents Chemother 56:231-42. 2012
    ..Addition of a β-lactamase inhibitor suppressed resistance even with the stably derepressed isolate. Tobramycin combination studies demonstrated resistance suppression in both the wild-type and the stably derepressed ..
  53. pmc Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection
    Bruce C Trapnell
    Cincinnati Children s Hospital Medical Center, OH 45229, USA
    Am J Respir Crit Care Med 185:171-8. 2012
    Fosfomycin/tobramycin for inhalation (FTI), a unique, broad-spectrum antibiotic combination, may have therapeutic potential for patients with cystic fibrosis (CF).
  54. pmc Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa
    Kristen N Schurek
    Centre for Microbial Diseases and Immunity Research, University of British Columbia, Room 232, 2259 Lower Mall, Lower Mall Research Station, Vancouver, British Columbia V6T1Z4, Canada
    Antimicrob Agents Chemother 52:4213-9. 2008
    ..library, consisting of approximately 5,800 mutants, was screened for twofold or greater increases in tobramycin resistance...
  55. doi Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions
    Gerard McCaughey
    CF and Airways Microbiology Research Group, Queen s University Belfast, United Kingdom
    J Cyst Fibros 11:163-72. 2012
    ..There is a need for new antibiotics or combination of antibiotics that possess activity against increasingly resistant cystic fibrosis (CF) respiratory pathogens such as Pseudomonas aeruginosa and MRSA...
  56. pmc Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa
    David L MacLeod
    Gilead Sciences, Inc, Seattle, Washington, USA
    Antimicrob Agents Chemother 56:1529-38. 2012
    ..In these studies, we demonstrate that fosfomycin synergistically enhances the activity of tobramycin in the presence of mucin...
  57. doi Controlling Pseudomonas aeruginosa persister cells by weak electrochemical currents and synergistic effects with tobramycin
    Tagbo H R Niepa
    Department of Biomedical and Chemical Engineering, Syracuse University, Syracuse, NY 13244, USA
    Biomaterials 33:7356-65. 2012
    ..5 μg/mL tobramycin together using SS304 electrodes...
  58. doi Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis
    David Berlana
    Departments of Pharmacy, Bellvitge University Hospital, Barcelona, Spain
    Pharmacotherapy 31:146-57. 2011
    ..outcomes in adults without cystic fibrosis who had Pseudomonas aeruginosa bronchial colonization and were receiving inhaled colistin or colistin plus tobramycin with those who were receiving inhaled tobramycin as outpatient treatment.
  59. doi EPR studies of free radicals decay and survival in gamma irradiated aminoglycoside antibiotics: sisomicin, tobramycin and paromomycin
    Sławomir Wilczyński
    Department of Biophysics, School of Pharmacy, Medical University of Silesia, Jednosci 8, 41 200 Sosnowiec, Poland
    Eur J Pharm Sci 45:251-62. 2012
    ..Free radicals in radiative sterilized sisomicin, tobramycin and paromomycin were studied by electron paramagnetic resonance (EPR) spectroscopy...
  60. ncbi In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin
    B Martha
    Division of Infectious Diseases, Hopital du Bocage, University Hospital, 21000 Dijon, France
    Clin Microbiol Infect 12:426-32. 2006
    ..MexXY efflux pump was investigated in vivo in an experimental model of PAP in rabbits treated with intravenous tobramycin. Three strains were used to induce PAP in rabbits: PAO1 (wild-type strain; MIC 1 mg/L), mutant 11B (mexX::Tn501; ..
  61. ncbi Effects of antibiotics on morphologic characteristics and migration of canine corneal epithelial cells in tissue culture
    D V Hendrix
    Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville 37901, USA
    Am J Vet Res 62:1664-9. 2001
    ..Cells treated with tobramycin and chloramphenicol grew similarly to control cells...
  62. ncbi Influence of gentamicin and tobramycin on binary biofilm formation by co-cultures of Burkholderia cepacia and Pseudomonas aeruginosa
    Amal G Al-Bakri
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester M13 9PL, England, UK
    J Basic Microbiol 45:392-6. 2005
    ..Pans, containing established biofilms, were swapped between CDFFs. Biofilms were treated either for 5 days with tobramycin (0.3 mg/ml) prior to pan-swapping, or with gentamicin (1 mg/ml) immediately following pan-swapping...
  63. ncbi Pharmacokinetic studies on tobramycin in horses
    H Hubenov
    Department of Surgery, Faculty of Veterinary Medicine, Trakia University, Stara Zagora, Bulgaria
    J Vet Pharmacol Ther 30:353-7. 2007
    The objective of the study was to evaluate the pharmacokinetics of tobramycin in plasma and urine in the horse (n = 7) after intravenous administration of a dose of 4 mg/kg b.w...
  64. doi In vitro efficacy of an ophthalmic drug combination against corneal pathogens of horses
    Nicole C Scotty
    University of Florida Veterinary Medical Center, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32608, USA
    Am J Vet Res 69:101-7. 2008
    ..To evaluate the in vitro efficacy of an ophthalmic drug combination against common corneal pathogens of horses...
  65. doi Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension
    Stephen V Scoper
    Virginia Eye Consultants, Norfolk, Virginia, USA
    Adv Ther 25:77-88. 2008
    TobraDex ophthalmic suspension (tobramycin 0.3%, dexamethasone 0.1%; Alcon Laboratories Inc, Fort Worth, Tex) is frequently used for inflammatory ocular conditions where a risk of bacterial ocular infection exists...
  66. pmc Systemic tobramycin concentrations during selective decontamination of the digestive tract in intensive care unit patients on continuous venovenous hemofiltration
    Meriel Mol
    Department of Intensive Care, Academic Medical Centre University of Amsterdam, P O Box 22660, 1100 DD Amsterdam, The Netherlands
    Intensive Care Med 34:903-6. 2008
    To study whether selective decontamination of the digestive tract (SDD) results in detectable serum tobramycin concentrations in intensive care unit (ICU) patients with acute renal failure treated with continuous venovenous hemofiltration ..
  67. ncbi Proteomic analysis of reaper 5' untranslated region-interacting factors isolated by tobramycin affinity-selection reveals a role for La antigen in reaper mRNA translation
    Paula Vazquez-Pianzola
    Department of Molecular Biology, Max Planck Institute for Biophysical Chemistry, Gottingen, Germany
    Proteomics 5:1645-55. 2005
    ..To understand the mechanisms of mRNA translation of a pro-apoptotic gene, reaper (rpr), we adapted the tobramycin-aptamer technique described by Hartmuth et al. (Proc. Natl. Acad. Sci...
  68. ncbi Dose-dependent effects of topical tobramycin in an animal model of Pseudomonas sinusitis
    Marcelo B Antunes
    Department of Otorhinolaryngology, Division of Rhinology, University of Pennsylvania, Philadelphia 19104, USA
    Am J Rhinol 21:423-7. 2007
    ..Despite their popularity, there is limited data in the literature to support its use. This study is the first to examine the effects of topical tobramycin in an animal model of Pseudomonas sinusitis.
  69. doi Simple and sensitive method for quantification of low tobramycin concentrations in human plasma using HPLC-MS/MS
    Milly E Attema-de Jonge
    Department of Pharmacy, Onze Lieve Vrouwe Gasthuis, Oosterpark 9, 1091 AC Amsterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 862:257-62. 2008
    After oral administration of tobramycin, as part of selective decontamination of the digestive tract (SDD) in critically ill patients, absorption of tobramycin from the gut into the blood may take place...
  70. doi Tolerability of loteprednol/tobramycin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, double-masked, parallel-group study
    Jimmy D Bartlett
    Department of Optometry, School of Optometry, University of Alabama at Birmingham, Birmingham, AL 35294 0010, USA
    Curr Med Res Opin 24:2219-27. 2008
    To compare the ocular comfort and tolerability of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T; Zylet) with dexamethasone 0.1%/tobramycin 0.3% (DM/T; TobraDex) in healthy volunteers.
  71. ncbi In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin
    A Novelli
    Department of Pharmacology, University of Florence, Italy
    J Chemother 7:355-62. 1995
    The occurrence of a postantibiotic effect (PAE) and postantibiotic leukocyte enhancement (PALE) of tobramycin, a natural aminoglycoside clinically used since the early 1970s, has been investigated in comparison to gentamicin on recent ..
  72. ncbi Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis
    W H Nikolaizik
    Dept of Paediatrics, University Hospital Essen, Germany
    Eur Respir J 20:122-6. 2002
    It has been established that inhaled tobramycin has a positive effect on respiratory function in Pseudomonas-aeruginosa positive patients with cystic fibrosis (CF)...
  73. ncbi The effectiveness of tobramycin and Ocuflox in a prophylaxis model of Staphylococcus keratitis
    J J Dajcs
    Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center in New Orleans, 70112, USA
    Curr Eye Res 23:60-3. 2001
    ..METHODS: One topical drop of Tobrex (0.3% tobramycin), tobramycin (0.3%) in the Tobrex vehicle with 0.05% dodecyl maltoside (DDM)/4...
  74. ncbi Efficacy and safety of aerosolized tobramycin in cystic fibrosis
    V B Pai
    Idaho State University and St Luke s Regional Medical Center, Boise, Idaho 83712, USA
    Pediatr Pulmonol 32:314-27. 2001
    Aerosolized tobramycin has been extensively used in cystic fibrosis (CF) patients in order to directly deliver the antibiotic to the endobronchial site of infection, and decrease toxicity by limiting systemic absorption...
  75. doi Shifting patterns of inhaled antibiotic use in cystic fibrosis
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98195 7740, USA
    Pediatr Pulmonol 43:874-81. 2008
    ..Our working hypothesis was that a shift from acute to chronic use of inhaled antibiotics has coincided with increased prevalence of use among CF patients...
  76. ncbi A comparison of topical chlorhexidine, ciprofloxacin, and fortified tobramycin/cefazolin in rabbit models of Staphylococcus and Pseudomonas keratitis
    Ping Bu
    Department of Ophthalmology, Loyola University Medical Center, Maywood, IL 60153, USA
    J Ocul Pharmacol Ther 23:213-20. 2007
    ..Chlorhexidine was evaluated as a potential topical therapy for experimental bacterial keratitis...
  77. doi Protective effect of edaravone against tobramycin-induced ototoxicity
    Monika Stenkvist Asplund
    Department of Otolaryngology, Head and Neck Surgery, University Hospital, Uppsala, Sweden
    Acta Otolaryngol 129:8-13. 2009
    ..that simultaneous treatment with the radical scavenger edaravone has an effective protective effect against tobramycin ototoxicity in rat...
  78. doi Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis
    Clare McCormick
    Department of Microbiology, University of Mississippi Medical Center, Jackson, MS, USA
    Curr Med Res Opin 24:1569-75. 2008
    To quantitatively determine, in a Pseudomonas keratitis model, the anti-inflammatory and bactericidal properties of a new formulation of tobramycin (0.3%) and dexamethasone (0.05%) that utilizes a xanthan gum vehicle.
  79. ncbi CF: an X-ray database to assess effect of aerosolized tobramycin
    Dubhfeasa M Slattery
    Division of Respiratory Diseases, Children s Hospital, Boston, Massachusetts, USA
    Pediatr Pulmonol 38:23-30. 2004
    This paper assesses the effectiveness of aerosolized tobramycin (TOBI) on cystic fibrosis (CF) lung disease, using a radiologic tool...
  80. ncbi Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial
    Dag Torfoss
    Cancer Clinic, Rikshospitalet Radiumhospitalet Medical Center, Oslo, Norway
    J Antimicrob Chemother 59:711-7. 2007
    ..We questioned this argument and hypothesized that tobramycin once daily was as efficacious as three times daily.
  81. ncbi Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients
    Joan R Badia
    UVIR Institut Clínic de Pneumologia i Cirurgia Toràcica, Barcelona, Spain
    J Antimicrob Chemother 54:508-14. 2004
    ..Delivery of antibiotics to the lower respiratory tract could potentially achieve antimicrobial bronchial drug concentrations without toxicity...
  82. ncbi Incorporation of tobramycin into biomimetic hydroxyapatite coating on titanium
    M Stigter
    IsoTis NV, Bilthoven, The Netherlands
    Biomaterials 23:4143-53. 2002
    ..immersed in a supersaturated calcium phosphate (SCP) solution containing 0, 100, 200, 400, 600 or 800 mg/l of tobramycin for 48 h at 37 degrees C. A carbonated hydroxyapatite (CHA) layer, approximately 40 microm thick, was formed...
  83. ncbi A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
    M E Hodson
    Royal Brompton and Harefield NHS Trust, London, UK
    Eur Respir J 20:658-64. 2002
    ..The purpose of this trial was to assess the efficacy and safety of tobramycin nebuliser solution (TNS) and nebulised colistin in CF patients chronically infected with P. aeruginosa...
  84. doi [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis]
    P Y Robert
    Service d Ophtalmologie, CHU Dupuytren, 2, avenue Martin Luther King, 87042 Limoges Cedex, France
    J Fr Ophtalmol 33:241-8. 2010
    ..These clinical signs appear quickly and are contagious. This study compares the clinical efficacy (signs and symptoms) and safety of azithromycin 1.5% eye drops with tobramycin 0.3%.
  85. ncbi Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial
    James E Peacock
    Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157 1042, USA
    Ann Intern Med 137:77-87. 2002
    ..Therapy with an aminoglycoside and a beta-lactam remains common empirical therapy for febrile neutropenic patients. Concerns of aminoglycoside-induced ototoxicity and nephrotoxicity have led to studies of alternate regimens...
  86. ncbi Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa
    Y L Wu
    School of Pharmacy, The Queen s University of Belfast, Medical Biology Centre, UK
    J Antimicrob Chemother 44:389-92. 1999
    The ability of combinations of azlocillin and tobramycin to prevent or delay resistance development in eight Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients was studied using chequerboard titration and in-vitro serial ..
  87. ncbi Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system
    David E Geller
    The Nemours Children s Clinic, 83 W Columbia St, Orlando, FL 32806 1101, USA
    Chest 123:28-36. 2003
    To determine whether tobramycin solution for inhalation (TSI) can be administered safely and more efficiently with a new-generation aerosol device, the AeroDose 5...
  88. doi Efficacy and safety of netilmycin/dexamethasone preservative-free and tobramycin/dexamethasone-preserved fixed combination in patients after cataract surgery
    Veronica Pianini
    UO Oculistica, Stabilimento Ospedaliero di Carrara, Azienda USL 1 di Massa Carrara, Italy
    J Ocul Pharmacol Ther 26:617-21. 2010
    To compare the efficacy and safety of preservative-free Netilmycin/Dexamethasone with that of preserved Tobramycin/Dexamethasone, postcataract surgery.
  89. ncbi Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis
    J A Bosso
    Department of Pharmacy Practice, College of Pharmacy, University of Utah, Salt Lake City 84112
    Pediatr Infect Dis J 7:171-6. 1988
    The efficacy of aztreonam was compared to that of standard therapy consisting of tobramycin and azlocillin in the treatment of acute pulmonary exacerbations of cystic fibrosis in a randomized, open trial...
  90. ncbi A component of innate immunity prevents bacterial biofilm development
    Pradeep K Singh
    Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
    Nature 417:552-5. 2002
    ..These findings reveal a specific anti-biofilm defence mechanism acting at a critical juncture in biofilm development, the time bacteria stop roaming as individuals and aggregate into durable communities...
  91. ncbi Crystal structure of a complex between the aminoglycoside tobramycin and an oligonucleotide containing the ribosomal decoding a site
    Quentin Vicens
    Institut de Biologie Moleculaire et Cellulaire du Centre National de la Recherche Scientifique, Modélisation et Simulations des Acides Nucléiques, UPR 9002, Universite Louis Pasteur, 15 rue Rene Descartes, 67084 Strasbourg Cedex, France
    Chem Biol 9:747-55. 2002
    ..containing the A site sequence complexed to the 4,6-disubstituted 2-deoxystreptamine aminoglycoside tobramycin. The three aminosugar rings making up tobramycin interact with the deep-groove atoms directly or via water ..
  92. ncbi A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study
    Alexander Chuchalin
    Scientific Research Pulmonology Institute, Russian State Medical University, Moscow, Russia
    Paediatr Drugs 9:21-31. 2007
    ..The purpose of this trial was to assess the efficacy and tolerability of a tobramycin highly concentrated solution for inhalation (TSI) [300mg/4mL; Bramitob when added to other antipseudomonal ..
  93. ncbi Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs?
    Heather L Vandenbussche
    Pharmacy Department, Bronson Methodist Hospital, Kalamazoo, MI 49007, USA
    Lancet 365:547-8. 2005
  94. ncbi Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa
    Gerard Lenoir
    Service of General Paediatrics, Necker Enfants Malades Hospital, Paris, France
    Paediatr Drugs 9:11-20. 2007
    ..This trial was designed to investigate the efficacy and safety of a highly concentrated (300mg/4mL) tobramycin solution for inhalation (TSI) [Bramitob] in patients with CF and P. aeruginosa infection.
  95. ncbi Experience with a once-daily dosing program of aminoglycosides in critically ill patients
    S E Buijk
    Dept of Surgical Intensive Care, Erasmus MC Rotterdam, P O Box 2040, 3000 CA Rotterdam, The Netherlands
    Intensive Care Med 28:936-42. 2002
    ..As aminoglycosides show concentration-dependent killing, once-daily aminoglycoside (ODA) regimens have been instituted. Data on experience with ODA regimens in critically ill patients are limited...
  96. ncbi Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy
    Ingrid M Hoffmann
    Department of Pediatrics, Wake Forest University School of Medicine Baptist Medical Center, Winston Salem, North Carolina 27157 1081, USA
    Pediatr Pulmonol 34:375-7. 2002
    ..a 20-year-old patient with cystic fibrosis who developed acute nonoliguric renal failure associated with inhaled tobramycin. Clinical evaluation and renal biopsy findings were consistent with aminoglycoside-induced changes...
  97. ncbi TOBI: reducing the impact of pseudomonal infection
    John Govan
    Department of Medical Microbiology, University of Edinburgh Medical School, Edinburgh EH8 9AG
    Hosp Med 63:421-5. 2002
    ..b>Tobramycin nebulizer solution (TOBI, Chiron Corporation Ltd, Hounslow) has been specifically formulated for use against P...
  98. ncbi The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis
    Jeffrey L Blumer
    Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    Chest 128:2336-46. 2005
    ..IV meropenem (40 mg/kg to 2 g q8h) or ceftazidime (5 mg/kg to 2 g q8h), each of which was administered with IV tobramycin (at a serum peak of > or = 8 microg/mL and a trough of < 2 microg/mL), as treatment for CF patients with ..
  99. ncbi Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance
    Rebecca M Landry
    Department of Chemistry, Northwestern University, Evanston, IL 60208, USA
    Mol Microbiol 59:142-51. 2006
    ..on mucin-coated surfaces developed large cellular aggregates and had increased tolerance to the antibiotic tobramycin compared with biofilms grown on glass...
  100. ncbi Acute renal failure associated with vancomycin- and tobramycin-laden cement in total hip arthroplasty
    Benjamin N Patrick
    The University of Montana and Community Medical Center, Missoula, MT 59812 1522, USA
    Ann Pharmacother 40:2037-42. 2006
    ..To describe 2 cases of acute renal failure (ARF) associated with the use of antibiotic-laden cement incorporated in total hip arthroplasties (THA)...
  101. ncbi Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia
    Manjari Joshi
    University of Maryland School of Medicine, R Adams Cowley Shock Trauma Center, Baltimore, MD 21201, USA
    Respir Med 100:1554-65. 2006
    ..Treatment groups had similar number of mean hospital days, readmission rates, and frequency of AEs. This study showed that P/T administered four times per day was as safe and efficacious as IMP in treating hospitalized patients with NP...

Research Grants66

  1. Use of Gallium to Prevent Pseudomonas Biofilm Formation
    Bradley Britigan; Fiscal Year: 2005
    ..aeruginosa biofilm formation and enhances its susceptibility to tobramycin. Gallium (Ca), a group IliA transition metal disrupts the Fe metabolism of many cell types...
  2. Antibiotic-mediated Adaptation of Pseudomonas aeruginosa
    LUCAS HOFFMAN; Fiscal Year: 2007
    ..aeruginosa responds specifically to subinhibitory concentrations of the antibiotic tobramycin with increased biofilm formation. Tobramycin-induced biofilms are more resistant to further antibiotic challenge...
  3. OCULAR PATHOGENESIS AND THERAPY OF BACTERIAL KERATITIS
    James Hill; Fiscal Year: 1993
    ..corneal scarring; 2) Determine if steroids (dexamethasone or prednisolone) plus antibiotics (ciprofloxacin or tobramycin) can reduce irreversible corneal scarring; 3) Determine if other agents such as nonsteroidal anti-inflammatory ..
  4. Developing D-methionine as an Aminoglycoside Otoprotectant
    Kathleen Campbell; Fiscal Year: 2007
    ..proof of concept data for gentamicin and amikacin otoprotection, to determine if D-met also protects against tobramycin-induced ototoxicity, and to ensure that D-met does not interfere with the antimicrobial action of these ..
  5. Developing D-methionine as an Aminoglycoside Otoprotectant
    KATHLEEN CHARLOTTE MURPHEY CAMPBELL; Fiscal Year: 2010
    ..proof of concept data for gentamicin and amikacin otoprotection, to determine if D-met also protects against tobramycin-induced ototoxicity, and to ensure that D-met does not interfere with the antimicrobial action of these ..
  6. Developing D-methionine as an Aminoglycoside Otoprotectant
    Kathleen Campbell; Fiscal Year: 2009
    ..proof of concept data for gentamicin and amikacin otoprotection, to determine if D-met also protects against tobramycin-induced ototoxicity, and to ensure that D-met does not interfere with the antimicrobial action of these ..
  7. Developing D-methionine as an Aminoglycoside Otoprotectant
    Kathleen Campbell; Fiscal Year: 2009
    ..proof of concept data for gentamicin and amikacin otoprotection, to determine if D-met also protects against tobramycin-induced ototoxicity, and to ensure that D-met does not interfere with the antimicrobial action of these ..
  8. Early Antipseudomonal Therapy in Cystic Fibrosis
    Bonnie Ramsey; Fiscal Year: 2007
    ..e., treatment provided systematically in quarterly cycles until the end of the 18-month study period. Inhaled tobramycin and oral ciprofloxacin have bean selected as first choice antimicrobials for this trial, based on a consensus ..
  9. Respirable ciprofloxacin aerosol for inhaled anthrax
    Brooks Hybertson; Fiscal Year: 2004
    ..Although several water-soluble antibiotics, including tobramycin, have been formulated for pulmonary delivery as inhaled aerosols, respirable particles of highly lipophilic ..
  10. SUPRAER, High Dose Rate Aerosol Drug Delivery
    DONOVAN YEATES; Fiscal Year: 2007
    ..SUPRAER will be used to generate aerosols of surfactant, tobramycin, insulin and mannitol...
  11. INHALED TOBRAMYCIN IN YOUNG CYSTIC FIBROSIS PATIENTS
    Bonnie Ramsey; Fiscal Year: 2003
    ..of this proposal is to determine the short-term microbiologic efficacy and safety of an inhaled antibiotic, tobramycin solution for inhalation (TOBI), in infants and young children with cystic fibrosis (CF) and documented ..
  12. FLUORESCENT LABELING OF NUCLEIC ACIDS
    LARRY MCLAUGHLIN; Fiscal Year: 2001
    ..We will examine the structure stabilizing abilities of Tobramycin, Neomycin B, and various analogues constructed on a Neamine core disaccharide...
  13. Beacon Aptamers for the Detection of Small Molecules
    Daniel Morse; Fiscal Year: 2006
    ..The selection strategy will be tested by using the antibiotic tobramycin as the target...
  14. INHALED AZTREONAM FOR CYSTIC FIBROSIS
    Alan Montgomery; Fiscal Year: 2006
    ..the ability of inhaled aztreonam (AI) to maintain or improve the clinical status following a 28-day course of tobramycin solution for inhalation...
  15. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    Margaret Rosenfeld; Fiscal Year: 2004
    ..The initial development of proposed model will be conducted utilizing aerosolized tobramycin, which has been shown to be safe and effective in the treatment of CF patients over six years of age and was ..